2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide
C26H35N5O2 — CID 151511352
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide
2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide (PubChem CID 151511352) has the molecular formula C26H35N5O2 and a molecular weight of 449.60 g/mol. Its IUPAC name is 2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide.
Molecular Properties
| Compound Name | 2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide |
|---|---|
| PubChem CID | 151511352 |
| Molecular Formula | C26H35N5O2 |
| Molecular Weight | 449.60 g/mol |
| Exact Mass | 449.28 |
| IUPAC Name | 2-amino-N-[(3S,5R)-5-[2-(4-benzylpiperazin-1-yl)-3-phenylpropanoyl]pyrrolidin-3-yl]acetamide |
| SMILES | NCC(=O)N[C@@H]1CN[C@@H](C(=O)C(Cc2ccccc2)N2CCN(Cc3ccccc3)CC2)C1 |
| InChI | InChI=1S/C26H35N5O2/c27-17-25(32)29-22-16-23(28-18-22)26(33)24(15-20-7-3-1-4-8-20)31-13-11-30(12-14-31)19-21-9-5-2-6-10-21/h1-10,22-24,28H,11-19,27H2,(H,29,32)/t22-,23+,24?/m0/s1 |
| InChIKey | PSNRMUQDCCDYDR-XAGPSQNTSA-N |
| XLogP | 0.79 |
| TPSA | 90.70 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 449.60 |
| LogP ≤ 5 | 0.79 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 151511352 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.